The Eighth Think Tank Symposium Series on Vaccine Solutions for Developing Countries
A Report of HAI
December 3-6, 2000
Novotel Mount Meru
Arusha, Tanzania
Sponsors
HAI
Cosponsors
Fogarty International Center of the United States International Health www.nih.gov/fic
Kilimanjaro Christian Medical Centre
Until There's A Cure Foundation www.utac.org
HIV Vaccines for Developing Countries: Subtype C was sponsored by HAI, with cosponsorship provided by the Fogarty International Center of the United States National Institutes of Health and the Until There's A Cure Foundation.
This report was written by Thumbi Ndung’u and Trevor Peter and is based upon the presentations and discussions that took place at the meeting. The report was edited by Philip Dwight Rotz and produced by HAI staff. For more information, contact HAI at 651 Huntington Avenue, Boston, Massachusetts 02115 USA (phone: +1-617-432-4400 fax: +1-617-432-4545 email: hai@hsph.harvard.edu).
TABLE OF CONTENTS
AFRICA-SPECIFIC VACCINE DESIGN ISSUES
The significance of Africa-specific vaccine design
The relevance of subtype and nonsubtype specificity
Vectors and delivery systems
HIV-1C reagents for vaccine design
PARAMETERS OF VACCINE TRIALS IN AFRICA
What is needed for clinical trials?
A better definition of acute infection
Issues of safety and toxicity in subjects who will not be closely monitored
Evaluations of attenuated infection in an African setting
THE HIV EPIDEMIC IN TANZANIA
Multiple viruses
Incidence rates
Overview of Harvard-Muhimbili Research
CASE STUDIES: DEVELOPING COUNTRY HIV VACCINE EXPERIENCE
Case study: Thailand
Case study: Uganda
CASE STUDIES: FUTURE OPPORTUNITIES
Case study: Nigeria
Case study: Botswana
PANEL DISCUSSION: FUTURE PLANS FOR VACCINE DEVELOPMENT
